Asia Deal Watch: Dong-A Brings In NeuroBo As Partner On Pair Of Cardiometabolic Candidates
Executive Summary
Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.
You may also be interested in...
Upsher-Smith Shuffles Portfolio With A Pair Of Deals
Sawai’s Upsher-Smith business in the US has announced a pair of deals that will see the firm expand an existing partnership with Appco for a “near-term generic product opportunity” as well as divesting two “dormant” ANDAs in favor of a focus on more immediate assets.
Bora Bulks Up With Move For Taiwan’s TWi
Bora Pharmaceuticals says it has become “the largest pharmaceutical group by volume in Taiwan” after acquiring TWi Pharmaceuticals.
Lupin And DKSH To Market Five Alvotech Biosimilars In The Philippines
Lupin’s Multicare Pharmaceuticals subsidiary in the Philippines will partner with distributor DKSH to market five Alvotech biosimilars. Alvotech’s biosimilars, which remain at the pre-approval stages, reference Prolia/Xgeva, Eylea, Simponi, and two more undisclosed molecules.